<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03897374</url>
  </required_header>
  <id_info>
    <org_study_id>02252019</org_study_id>
    <nct_id>NCT03897374</nct_id>
  </id_info>
  <brief_title>Strategic Targeting for Optimal Prevention of Cancer</brief_title>
  <acronym>STOP-Cancer</acronym>
  <official_title>Strategic Targeting for Optimal Prevention of Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>ClinLogic LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>ClinLogic LLC</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary goal of the study is to record data over the observation period to evaluate the
      clinical benefit of using hereditary cancer genomic diagnostics to assess overall hereditary
      genetic cancer risk profile and to help guide physicians to pursue preventative measures,
      which may lead to early detection and treatment of the condition.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Data collection will be limited to study subjects 18 years or older who have received a
      hereditary cancer genomic diagnostic test results no more than 90 days prior to consent. The
      genes evaluated may be modified from time to time by the Sponsor as the body of knowledge
      expands and important additional pathways are identified. The list of appropriate genes that
      may be considered by the treating physician includes but are not necessarily limited to the
      following genes: ATM, BARD1, BRCA1, BRCA2, BRIP1, CDH1, CHEK2, EPCAM, MLH1, MRE11A, MSH2,
      MSH6, NBN, PALB2, PMS2, PTEN, RAD50, RAD51C, RAD51D, RINT1, TP53 and XRCC2. These subjects
      must also meet medical necessity for hereditary cancer genomic testing; and allow physician
      to test based on medical necessity. Hereditary Cancer testing will be diagnostic rather than
      screening in nature.

      Study subject data will be collected only if medical necessity was established, subject
      agreed to test based on medical necessity and hereditary cancer genomic test was ordered by a
      physician related to individual study subject care considerations. The hereditary Cancer
      testing is independent of this data-collection, non- interventional study. The hereditary
      cancer genomic test must be ordered according to the individual study subject care
      considerations, it is not protocol specified, and will not be considered as &quot;research&quot; that
      is part of the study. Rather, the use of hereditary cancer genomic testing serves as criteria
      for eligibility in the study and must have been ordered for medical necessity and results
      received no less than 90 days prior before data is collected.

      The primary goal of the study is to record data over the observation period to evaluate the
      clinical benefit of using hereditary cancer genomic diagnostics to assess overall hereditary
      genetic cancer risk profile and to help guide physicians to pursue preventative measures,
      which may lead to early detection and treatment of the condition; and to record physician
      recommended treatments and subject's brief medical history, demographic data; and
      investigator specialty.

      Such genetic test results and recommended treatments can be tabulated and analyzed to
      demonstrate the clinical utility of using hereditary cancer genomic diagnostics for
      prevention, early detection and treatment of the condition.

      The data will be collected retrospectively for a total of 120 no more than 150 days over the
      observation period in one (1) Case Report Form (survey). Similarly, the secondary objectives
      will be tabulated over the same observation period.

      An interim analysis of data will be performed to determine if the study subject data
      collection should be increased or decreased in order to fulfill study objectives.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 26, 2019</start_date>
  <completion_date type="Anticipated">August 1, 2024</completion_date>
  <primary_completion_date type="Anticipated">April 1, 2024</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>120 Days</target_duration>
  <primary_outcome>
    <measure>Genomic cancer screen</measure>
    <time_frame>120 Days</time_frame>
    <description>A study subject is known to have personal and/or family history of cancer known to be influenced by genetic variation.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Genomic cancer screen</measure>
    <time_frame>120 Days</time_frame>
    <description>A genotype known to be a predisposition for cancer.</description>
  </primary_outcome>
  <enrollment type="Anticipated">120000</enrollment>
  <condition>Early Detection of Cancer</condition>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Genetic Testing</intervention_name>
    <description>Buccal swab</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Individuals, ages 18 years or older.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Study subjects may be included in the Clinical Trial if they meet all of the following
             inclusion criteria:

               -  individuals, ages 18 years or older;

               -  must have met medical necessity for hereditary cancer genomic testing and allowed
                  the physician to test based on medical necessity;

               -  hereditary cancer diagnostic test was ordered by a physician related to
                  individual subject care considerations.

               -  hereditary cancer diagnostic test was received no more than 90 days prior to data
                  collection.

        one or more of the following must be present:

          -  study subject has more than one cancer; or

          -  study subject has multiple close family members with a cancer diagnosis under the age
             of fifty; or

          -  study subject has three or more close family members with different types of cancer;
             or

          -  study subject has had family that has previously had cancer genetics testing and
             mutations were identified.

        Exclusion Criteria:

          -  Study subjects will be excluded from the study if any of the following criteria apply:
             â€¢ study subject is currently hospitalized or incarcerated;

               -  study subject's medical and medication history is unavailable over the 90-days
                  preceding and following data collection;

               -  study subject is unable to provide an accurate history due to mental incapacity

               -  study subject is currently abusing illicit and/or prescription drugs;

               -  study subject is known to have undergone prior hereditary cancer diagnostic
                  testing for genes specific to the targeted genes, exclusive of the CGx test
                  relating to the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_contact>
    <last_name>Diana Messir</last_name>
    <phone>833-226-7545</phone>
    <email>Diana@integritycro.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>MD@Home</name>
      <address>
        <city>York</city>
        <state>Pennsylvania</state>
        <zip>17403</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marvin Inscore</last_name>
      <phone>717-467-1201</phone>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>March 26, 2019</study_first_submitted>
  <study_first_submitted_qc>March 28, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">April 1, 2019</study_first_posted>
  <last_update_submitted>March 30, 2020</last_update_submitted>
  <last_update_submitted_qc>March 30, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 31, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

